In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
Science on heart failure

Watch on-demand webinars on Late-Breaking Trials, and explore clinical cases, important HFA position papers, and more.

 

Access now

European Journal of Heart Failure

Advancing Knowledge in the Field of Heart Failure Management

 

The European Journal of Heart Failure (EJHF) is dedicated to the advancement of knowledge in the field of heart failure management.

The journal publishes reviews and editorials to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as clinical, social and population sciences all form part of the discipline.

Fast Facts

  • Editor-in-chief: Marco Metra (IT)
  • Current volume: 24 (year 2022)
  • Issues per subscription: 12
  • Impact Factor 2020:  15.534

 

Editor in chief History

 

Name Start Date End Date
Professor John Cleland 01/01/1999 31/12/2004
Professor Karl Swedberg 01/01/2005 31/12/2009
Professor Dirk J. Van Veldhuisen 01/01/2010 31/12/2014
Professor Marco Metra 01/01/2015  
Updates on latest articles

Updates on latest articles

 

Receive the table of contents in your mailbox.

Track topics and authors important to you and receive articles in your mailbox.

For Authors

Before being published, all manuscripts go through double-blind peer review by experienced international experts.


Most recent articles from EJHF

18 Jan 2022
Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003–2017
Author(s): Deewa Zahir, Anders Bonde, Christian Madelaire, Morten Malmborg, Jawad H. Butt, Emil Fosbol, Gunnar Gislason, Christian Torp‐Pedersen, Charlotte Andersson, Patrick Rossignol, John J.V. McMurray, Lars Kober, Morten Schou
14 Jan 2022
Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)
Author(s): Rudolf A. de Boer, Stephane Heymans, Johannes Backs, Lucie Carrier, Andrew J.S. Coats, Stefanie Dimmeler, Thomas Eschenhagen, Gerasimos Filippatos, Lior Gepstein, Jean‐Sebastien Hulot, Ralph Knöll, Christian Kupatt, Wolfgang A. Linke, Christine E. Seidman, C. Gabriele Tocchetti, Jolanda van der Velden, Roddy Walsh, Petar M. Seferovic, Thomas Thum
17 Jan 2022
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
Author(s): Daniela Tomasoni, Gregg C. Fonarow, Marianna Adamo, Stefan D. Anker, Javed Butler, Andrew J.S. Coats, Gerasimos Filippatos, Stephen J. Greene, Theresa A. McDonagh, Piotr Ponikowski, Giuseppe Rosano, Petar Seferovic, Muthiah Vaduganathan, Adriaan A. Voors, Marco Metra
12 Jan 2022
Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone
Author(s): Juan B. Ivey‐Miranda, Friedrich Wetterling, Robert Gaul, Stephen Sheridan, Jennifer L. Asher, Veena S. Rao, Christopher Maulion, Devin Mahoney, Alexandre Mebazaa, Alastair P. Gray, Daniel Burkhoff, Martin R. Cowie, Zachary L. Cox, Javed Butler, Marat Fudim, Kenneth McDonald, Kevin Damman, Barry A. Borlaug, Jeffrey M. Testani